CURE’s myelodysplastic syndrome (MDS) page is an extensive resource of cancer information featuring the latest myelodysplastic syndrome news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on MDS.
September 23rd 2022
From NFL Hall of Famer Shannon Sharpe and Monty Python member sharing their cancer diagnoses to “Good Morning America” promoting Be The Match, here’s what’s happening in the cancer space this week.
September 14th 2022
My new cancer treatment hardly has any side effects, making me wonder if researchers are focusing on making their drugs more tolerable for patients.
September 1st 2022
The last year was tough, but with a new cancer treatment center and other opportunities, I’m going to sit tight and bloom where planted.
August 31st 2022
The FDA’s decision allows patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome — types of blood cancer — to continue enrolling on the TakeAim Leukemia trial.
August 23rd 2022
The Food and Drug Administration put a full clinical hold on a study of the novel drug FHD-286 in patients with acute myelogenous leukemia and myelodysplastic syndrome after study data showed an increase in a potentially fatal side effect.
August 17th 2022
Cancer and COVID-19 took away my yearly “benchmarks” of time, when I fly out to see friends and family.
August 10th 2022
I must remember to be kind to myself, and not compare my current abilities to my pre-cancer days.
August 3rd 2022
Enrollment has begun on a phase 3 clinical trial assessing the safety and efficacy of an investigational cell therapy in patients with acute myeloid leukemia, acute lymphocytic leukemia and myelodysplastic syndromes.
July 26th 2022
The findings support future studies of assessing the safety and efficacy of the novel drug-chemotherapy combination as a maintenance strategy following stem cell transplantation across a range of blood cancers, according to the study authors.
July 14th 2022
The decision to be treated locally or at a large research center can be a difficult one, but I am lucky enough to have both.
June 14th 2022
I’ve experienced fatigue from cancer before but contracting COVID-19 took it to a whole other level.
June 1st 2022
The expertise, guidance and overall compassion of Katherine Caprinolo, B.S.N., RN have quite literally helped me survive these past two years.
May 20th 2022
Cancer is a dangerous disease that comes with many difficult decisions, making me constantly feel like I’m living on the edge.
April 28th 2022
Well-meaning comments can come off as bothersome — or even hurtful — to me as I navigate cancer.
April 15th 2022
Earlier in the year, clinical trials assessing magrolimab for myelodysplastic syndrome and acute myeloid leukemia were put on a partial clinical hold, but now the FDA said that they can start enrolling patients again.
April 14th 2022
Early 2022 was difficult for me, with the death of my dog and some difficult cancer-related situations, but thankfully, I know wonderful people who helped pull me out of my slump.
January 28th 2022
All clinical trials investigating the combination of magrolimab and the chemotherapy Onureg have been paused due to unforeseen serious side effects experienced by patients with various blood cancers receiving the treatment.
December 13th 2021
Most patients with acute myeloid leukemia and myelodysplastic syndrome achieved strong antibody responses to COVID-19 vaccination, according to recent study results.
November 18th 2021
A cancer survivor explains how the new treatments coming out for all types of cancer give her hope. “If we are diagnosed today, a cure or remission may come out next week or next month, or next year to give us additional time to live,” she writes.
November 18th 2021
A phase 2 trial of aspacytarabine (BST-236) was initiated in patients with AML and MDS.
September 30th 2021
A cancer survivor explains why each person experiences cancer differently – from side effects to treatments and more.
August 10th 2021
A patient with MDS writes about facing fears during the treatment journey.
August 4th 2021
How are myelodysplastic syndromes diagnosed and staged? What causes them? An expert from Moffit Cancer Center offers insight.
July 22nd 2021
The FDA will expedite the development and review of the drug combination to treat untreated intermediate- high- and very high-risk myelodysplastic syndrome.
April 2nd 2021
Previously, Vidaza alone showed poor response rates for patients with TP53-mutated, myelodysplastic syndromes and acute myeloid leukemia, but adding the novel agent eprenetapopt improved response rates and overall survival in this patient population.